3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Unknown
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
1
Conditions
Uterine Cervical Neoplasms
1
Sarcoma, Ewing
1
Recurrence
1
Ovarian Neoplasms
1
Osteosarcoma
1
Lymphoma, T-Cell, Peripheral
1
Lymphoma, Mantle-Cell
1
Lymphoma, Large B-Cell, Diffuse
1
Lymphoma, Follicular
1
Lymphoma
1
HR-positive, HER2-negative and PIK3CA Mutation Advanced Breast Cancer
1
Chondrosarcoma
1
Interventions
Ifosfamide
30
Methotrexate
27
Doxorubicin
25
Cyclophosphamide
24
Cisplatin
22
Filgrastim
18
Etoposide
17
Gemcitabine
16
Leucovorin
14
Magnetic Resonance Spectroscopy
11
Temozolomide
10
cabozantinib
9
apatinib
9
Specimen Handling
9
Carboplatin
9
fludarabine
8
X-Rays
8
Nivolumab
8
Neoadjuvant Therapy
8
Irinotecan
8
Granulocyte Colony-Stimulating Factor
8
Docetaxel
8
Zoledronic Acid
7
Vincristine
7
Sirolimus
7
Radiotherapy
7
Phantoms, Imaging
7
Biopsy
7
Topotecan
6
Mesna
6
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Interventional
×
Osteosarcoma
×
TQ-B3525
×
Clear all
NCT04690725
2020-12-31
TQBSP
Peking University People's Hospital
Phase 1/2
Unknown
29 enrolled